Provectus Pharmaceuticals Inc. (PVCT.OB) Will Present at the Wall Street Analyst Conference
Provectus Pharmaceuticals Inc. (PVCT.OB) is a company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive, and more economical than conventional therapies. The company has also developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs -- PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis and atopic dermatitis. The company has received orphan drug designation from the FDA for PV-10. Provectus announced that on September 10th,…